目的 觀察前列地爾聯(lián)合阿替普酶治療急性腦梗死的臨床療效。方法 選擇2011年12月-2015年4月煙臺(tái)龍礦中心醫(yī)院收治的急性腦梗死患者120例,隨機(jī)分成對(duì)照組和治療組,每組各60例。對(duì)照組給予注射用阿替普酶,5 mg溶于10 mL生理鹽水中,10 s內(nèi)靜脈推注,45 mg溶于100 mL生理鹽水中,60 min內(nèi)靜脈滴注。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注前列地爾注射液,20 μg溶于250 mL生理鹽水,1次/d,兩組患者均連續(xù)治療14 d。觀察兩組的臨床療效,比較兩組治療前后國立衛(wèi)生研究院卒中量表(NIHSS)評(píng)分、日常生活能力指數(shù)(BI)、血管再通情況和腦梗死灶體積。結(jié)果 治療后,對(duì)照組和治療組總有效率分別為86.67%、93.33%,兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組患者的NIHSS評(píng)分較治療前明顯下降,BI評(píng)分較治療前明顯升高,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組NIHSS評(píng)分和BI評(píng)分的改善程度優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組血管再通情況比較差異無統(tǒng)計(jì)學(xué)意義。兩組患者的腦梗死灶體積均較治療前明顯縮小,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組的治療前后差明顯大于對(duì)照組(P<0.05)。結(jié)論 前列地爾聯(lián)合阿替普酶治療急性腦梗死療效顯著,能夠顯著改善患者的神經(jīng)功能缺損癥狀,提高日常生活活動(dòng)能力,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacies of Kanglixin Capsules combined with mannatide in treatment of liver cancer. Methods Patients (86 cases) with liver cancer from February 2014 to July 2015 in People's Hospital of Yuxi City were divided into control group (43 cases) and treatment group (43 cases). All patients were given necessary chemotherapy and lipiodol embolization therapy, once a week, and were treated for 2 weeks. Based on the foresaid, the patients in the control group were iv administered with Mannatide Injection, 10 mg added into normal saline 250 mL, once daily. The patients in the treatment group were po administered with Kanglixin Capsules on the basis of the control group, 3 grains/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of survival quality, immune function and serum matrix metalloproteinase levels in two groups were compared. Results After treatment, ORR and CBR in the control group were 41.86% and 74.42%, respectively, accordingly, 65.12% and 90.70% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, improvement rate of survival quality in the control and treatment group were 74.42% and 93.02%, respectively, and the difference was statistically significant (P < 0.05). After treatment, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ were increased (P < 0.05); And the changes of immune function in treatment were more significant than those in control group (P < 0.05). After treatment, the serum MMP-2 and MMP-9 levels decreased more significantly than those before treatment (P < 0.05). But the reduction in treatment group was more significant than those in the control group (P < 0.05). Conclusion Kanglixin Capsules combined with Mannatide Injection has a good clinical efficacy in the treatment of hepatocellular carcinoma, and can improve the immune function and survival quality, which has a certain clinical application value.